In wake of third straight mid-stage setback, AnaptysBio looks to punt IL-36 drug — even as PhIII goes on
Despite a new Phase II flop, AnaptysBio says it remains “optimistic” on its lead drug — it just doesn’t want to be the one taking the drug all the way through.
AnaptysBio had set up a slate of studies for imsidolimab, an antibody blocking IL-36R, and already scrapped two indications — severe palmoplantar pustulosis and acne — after the trials failed. Its longtime CEO abruptly resigned after the last trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.